 Moneycontrol.com | Natco Pharma inks pact with Mabxience IBNLive.com Three of these products -Trastuzumab, Bevacizumab, Rituximab belong to the oncology segment, while Etanercept is for auto-immune disease, Natco said in a statement. Natco's obligations under the agreement will include manufacture of drug products, ... Natco Pharmaceuticals inks pact with Swiss firm Chemo Sa Lugano for purchase ... Natco Pharma Signs Pact With Mabxience Natco to enter bio-generics; signs up with Mabxience |
